Scarica l'app Stockscreener
0.013
38.10%
-0.008
Precedente Chiudi:
$0.021
Aprire:
$0.013
Volume 24 ore:
220
Relative Volume:
0.88
Capitalizzazione di mercato:
$N/A
Reddito:
$13.53M
Utile/perdita netta:
$-44.07M
Rapporto P/E:
-0.000461
EPS:
-28.2101
Flusso di cassa netto:
$-23.86M
1 W Prestazione:
-38.10%
1M Prestazione:
-38.10%
6M Prestazione:
-87.00%
1 anno Prestazione:
-85.40%
Intervallo 1D:
$0.013
$0.013
Intervallo di 1 settimana:
$0.013
$0.013
Portata 52W:
$0.0116
$0.1956
Telesis Bio Inc Stock (TBIO) Company Profile
Nome
Telesis Bio Inc
Settore
Industria
Telefono
-
Indirizzo
-
Confronta TBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TBIO
Telesis Bio Inc
|
0.013 | 0 | 13.53M | -44.07M | -23.86M | -28.21 |
|
ABT
Abbott Laboratories
|
125.12 | 220.33B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
96.11 | 140.06B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
353.11 | 134.83B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.48 | 126.02B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.80 | 49.23B | 5.88B | 1.34B | 799.60M | 2.3489 |
Telesis Bio Inc Stock (TBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-03-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| 2021-03-18 | Downgrade | Truist | Buy → Hold |
| 2020-10-05 | Iniziato | Goldman | Buy |
| 2020-07-07 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-06 | Iniziato | William Blair | Outperform |
| 2020-06-26 | Iniziato | SunTrust | Buy |
| 2019-07-22 | Iniziato | Jefferies | Buy |
| 2019-06-18 | Iniziato | ROTH Capital | Buy |
| 2018-12-24 | Iniziato | H.C. Wainwright | Buy |
| 2018-07-23 | Iniziato | Citigroup | Buy |
| 2018-07-23 | Iniziato | Evercore ISI | Outperform |
| 2018-07-23 | Iniziato | Leerink Partners | Outperform |
Mostra tutto
Telesis Bio Inc Borsa (TBIO) Ultime notizie
Statement of Changes in Beneficial Ownership (4) - ADVFN
Current Report Filing (8-k) - ADVFN
Small Company Offering and Sale of Securities Without Registration (d) - ADVFN
Layoff Tracker: GSK, Sail, BioNTech Cut Staff for Second Time This Year - BioSpace
Global mRNA Synthesis and Manufacturing Market to Increase at a Steady Growth Rate of ~4% by 2032 | DelveInsight - GlobeNewswire
Telesis Bio Inks Regeneron Deal - San Diego Business Journal
Regeneron Pharmaceuticals, Inc. (REGN) Shares Plunge Despite Positive Phase 3 Itepekimab Results - Insider Monkey
Telesis Bio and Regeneron Partner on Gene Synthesis - Technology Networks
Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis - Yahoo Finance
Driving Synthetic Biology Forward Through Adoption of Technology Enabling Rapid DNA and mRNA Synthesis - MedCity News
What is going on with the stock tbio - AInvest
Telesis Bio Bullish on Future After Whirlwind Year - San Diego Business Journal
FT ranking: The Americas’ Fastest-Growing Companies 2025 - Financial Times
Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis - Yahoo Finance
Nuclera appoints William J. Kullback as Non-Executive Director - Cambridge Network
From California to Cambridge: finance ace strengthens Nuclera board - Business Weekly
Carver Bancorp Leads 3 Noteworthy US Penny Stocks - simplywall.st
Telesis Bio secures $3 million in promissory notes By Investing.com - Investing.com Nigeria
Telesis Bio Inc. Faces Financial Challenges Amidst Revenue Decline - TipRanks
Telesis Bio Inc. (TBIO) Quarterly 10-Q Report - qz.com
Telesis Bio's Chief Legal Officer To Leave Post This Week - Law360
One new option listing and ten option delistings on October 21st - TipRanks
Technical Analysis of Telesis Bio, Inc. (OTC:TBIO) - TradingView
Why Telesis Bio Shares Are Trading Higher By Around 110%; Here Are 20 Stocks Moving Premarket - TradingView — Track All Markets
Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis - Yahoo Finance
Is Telesis Bio Inc. on the Brink of a Major Breakthrough? - timothysykes.com
Telesis Bio Inc. (NASDAQ: TBIO)Share Price - intelligentinvestor.com.au
Codex DNA stock plunges to 52-week low of $1.65 - Investing.com India
Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market - Stock Titan
Telesis Bio reshuffles board, appoints new chairs - Investing.com India
Telesis Bio completes sale of subsidiary EtonBio - Investing.com
Yuan Yang completed the acquisition of Eton Bioscience, Inc. from Telesis Bio, Inc. - marketscreener.com
Enzymatic DNA Synthesis Market Size | Industry Report 2033 - Grand View Research
Telesis Bio, Inc. Approves Board Changes - MarketScreener
DNA Synthesis Market Size, Share | Growth Report [2025-2032] - Fortune Business Insights
Telesis Bio appoints new CEO as founder steps down - Investing.com
Telesis Bio Announces Select Preliminary Fourth Quarter 2023 Financial Results - Stock Titan
Press Release Service: Enzymatic DNA Synthesis Market to Surge to US$2.11 Billion by 2028 Driven by Advances in Synthetic Biology and Genetic Engineering TechnologiesResearchAndMarkets.com - CRISPR Medicine News
Telesis Bio: Q3 Earnings Snapshot - qz.com
New research finds that despite the stereotypes, women actually negotiate their salaries more than men - Fortune
Telesis Bio to Report Second Quarter Financial Results on Thursday, August 10, 2023 - FinancialContent
Enzymatic DNA Synthesis Market 2022: Explore Top Factors that Will Boost the Global Market by 2028 - openPR.com
Telesis Bio Announces First Commercial Shipment of BioXp® Select DNA Cloning Kit - Technology Networks
Telesis Bio Announces Closing of $28.0 Million Private Placement of Preferred Stock And Warrants to Purchase an Additional $46.2 Million of Common Stock - The Globe and Mail
Telesis Bio, Inc. announced that it expects to receive $28 million in funding from Novalis Capital Partners LLC, Northpond Ventures, LLC, BroadOak Capital Partners LLC, Investment Arm and another investor - marketscreener.com
Telesis Bio to Report First Quarter Financial Results on Thursday, May 11, 2023 - Koreabizwire
Eyepoint Pharmaceuticals (NASDAQ:EYPT), GeoVax Labs (NASDAQ:GOVX), Telesis Bio (NASDAQ:TBIO), Organovo Holdings (NASDAQ:ONVO), TRACON Pharmaceuticals (NASDAQ:TCON), and Abivax: Six Biotech Companies, Six Strategies - The Wall Street Transcript
Telesis Bio Releases BioXp® Select Kits to Enable DNA Amplification and Scale-up - Stock Titan
Telesis Bio Releases BioXp® Select mRNA Synthesis Kit To Expand the Utility, Speed and Impact of Its Automated Synthetic Biology Workstation - Technology Networks
Telesis Bio: Q4 Earnings Snapshot - KION Central Coast
Synthetic Biology Startup Molecular Assemblies Ships First DNA From New San Diego Facility - Forbes
Telesis Bio Inc Azioni (TBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.14%
0.05%
Capitalizzazione:
|
Volume (24 ore):